1. Academic Validation
  2. Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib

Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib

  • Dig Liver Dis. 2023 May 23;S1590-8658(23)00618-7. doi: 10.1016/j.dld.2023.05.010.
Jin He 1 Fan Wu 1 Junfeng Li 1 Qianxi Deng 1 Jun Chen 1 Pengtao Li 2 Xianyao Jiang 3 Kun Yang 1 Shuman Xu 1 Zhongxiang Jiang 1 Xiaoqing Li 1 Zheng Jiang 4
Affiliations

Affiliations

  • 1 Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
  • 2 Department of Neurosurgery, Peking Union Medical College Hospital, Beijing 100044, China.
  • 3 Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, Haikou 570100, China.
  • 4 Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: jiangz1753@tom.com.
Abstract

Background: Hepatocellular carcinoma (HCC) is a highly vascularized tumor with a poor prognosis. Novel vascular-related therapeutic targets and prognostic markers remain urgently needed.

Aims: To investigate the role and mechanism of CLCA1 in hepatocellular carcinoma.

Methods: Immunofluorescence, Co-immunoprecipitation and rescue experiment were used to determine the specific mechanisms of CLCA1. Chemosensitivity assay was used to measure the impact of CLCA1 on Sorafenib.

Results: CLCA1 was dramatically downregulated in hepatocellular carcinoma cell lines and tissues. Ectopic expression of CLCA1 induced cell Apoptosis and G0/G1 phase arrest while suppressed cell growth, inhibited migration and invasion, reversal of epithelial mesenchymal transition in vitro and reduced xenograft tumor growth in vivo. Mechanistically, CLCA1 could co-localize and interact with TGFB1, thereby suppressing HCC angiogenesis through the TGFB1/SMAD/VEGF signaling cascade in vitro and in vivo. Moreover, CLCA1 also enhanced the sensitivity of HCC cells to the first-line targeted therapy, Sorafenib.

Conclusion: CLCA1 sensitizes HCC cells to Sorafenib and suppresses hepatocellular carcinoma angiogenesis through downregulating TGFB1 signaling cascade. This newly identified CLCA1 signaling pathway may help guide the anti-angiogenesis therapies for hepatocellular carcinoma. We also support the possibility of CLCA1 being a prognostic biomarker for hepatocellular carcinoma.

Keywords

Anti-angiogenesis; Chemosensitivity; Gene expression; Prognostic.

Figures
Products
Inhibitors & Agonists
Other Products